HIGH-DRUG-LOADING ANTIBODY-DRUG CONJUGATE AND ITS APPLICATIONS
RU2026105032APending Publication Date: 2026-07-06CSPC MEGALITH BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- RU · RU
- Patent Type
- Applications
- Current Assignee / Owner
- CSPC MEGALITH BIOPHARMACEUTICAL CO LTD
- Filing Date
- 2024-07-31
- Publication Date
- 2026-07-06
AI Technical Summary
Technical Problem
Existing antibody-drug conjugates (ADCs) differ in pharmacokinetics and stability, resulting in high toxicity and poor efficacy of drugs.
Method used
By introducing reactive glutamine into the constant region of the antibody, covalent coupling is performed using microbial transglutaminase (mTGase), an antibody-drug conjugate with high drug load is formed, and chemical methods such as click chemistry Further optimize the DAR value.
Benefits of technology
High drug load and uniformity of antibody-drug conjugates are achieved, reducing drug toxicity, and improving drug efficacy and stability.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000001
Abstract
An antibody-drug conjugate having a high drug load and the use thereof. The antibody-drug conjugate has a high drug-antibody ratio (DAR) and comprises an antibody and a drug conjugate moiety, wherein a constant region of the antibody comprises reactive glutamine. Also provided are the preparation method for and the use of the antibody-drug conjugate having a high drug load.
Need to check novelty before this filing date? Find Prior Art